Abbvie 3110-305-002 Pediatric Migraine Clinical Study
Austin Regional Clinic physicians constantly work to improve the care given to all our patients. We are dedicated to offering unique options for our patients and helping them reach their ideal health goals. Part of this dedication involves making clinical research available. Clinical research makes it possible to discover the benefits, risks, and safety of commercially available and investigational medications.
Research standards are very strict to help make studies as safe as possible. Teams of government and research experts have already reviewed each study we conduct to minimize any study risks. Austin Regional Clinic has decided to be involved in this research study because we believe it can potentially benefit our patients.
About the Abbvie 3110-305-002 pediatric migraine clinical study
The purpose of this study is to evaluate safety and efficacy of two doses of Ubrogepant (low and high) when administered for the acute treatment of migraine in pediatric subjects six to 17 years of age.
By participating in this study, you would be contributing to the development of groundbreaking technology with the potential to benefit many people in the future. ARC is one of the many study centers in the United States participating in this research study.
What to expect
We are currently seeking candidates for a clinical research study. During the study, patients can expect:
- To come to three total visits. These visits will include giving medical history, physical examination, vital signs, urinalysis, ECG, C-SSRS assessment, PedsQL, taking study medication, two blood draws, and utilizing eDiaries.
Eligibility criteria
All participants must:
- Be 6-17 years of age
- Have a history of migraines for at least six months
Location
Request to participate
Please contact our ARC Clinical Research team to request to participate by calling 737-247-7240.